ABSTRACT
OBJECTIVE: To investigate the ZAP-70 and CD38 expressions and their combined expressions in Sudanese B-CLL patients and their relationships with clinical and hematological characteristics as well as the disease staging at presentation. RESULTS: In the present cross-sectional descriptive study, analysis of ZAP-70 expression showed that 36/110 (32.7%) patients positively expressed ZAP-70 and insignificant higher presentation in intermediate and at advanced stages as well as no correlation was seen with hematological parameters and clinical features compared with negatively ZAP-70, on the other hand, 41/110 (37.3%) were CD38+ and no significant correlation was shown with the stage at presentation, clinical characteristics (except Splenomegaly, P = 0.02) and hematological parameters. However, in combined expressions of both ZAP-70 and CD38 together, 20/110 (18.2%) were concordantly ZAP-70+/CD38+, 53/110 (48.2%) concordantly ZAP-70-/CD38- and 37/110 (33.6%) either ZAP-70+ or CD38+, and these three groups showed insignificant correlation with clinical (except Splenomegaly, P = 0.03) and hematological parameters, and the stage at presentation. Our data showed the combined analysis of these two markers, lead to classify our patients into three subgroups (either concordant positive, negative or discordant expressions) with statistically insignificant correlation with clinical presentation (except Splenomegaly), hematological parameters and stage at presentation of B-CLL patients.
Subject(s)
ADP-ribosyl Cyclase 1/genetics , Biomarkers, Tumor/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Membrane Glycoproteins/genetics , Splenomegaly/diagnosis , ZAP-70 Protein-Tyrosine Kinase/genetics , ADP-ribosyl Cyclase 1/blood , ADP-ribosyl Cyclase 1/immunology , Adult , Aged , B-Lymphocytes/immunology , B-Lymphocytes/pathology , Biomarkers, Tumor/blood , Biomarkers, Tumor/immunology , Cross-Sectional Studies , Female , Gene Expression , Humans , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Membrane Glycoproteins/blood , Membrane Glycoproteins/immunology , Middle Aged , Neoplasm Staging , Prospective Studies , Splenomegaly/genetics , Splenomegaly/immunology , Splenomegaly/pathology , Sudan , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/immunologyABSTRACT
BACKGROUND: Serum antinuclear antibodies (ANAs) are positive in some patients with chronic lymphocytic leukemia (CLL), but the prognostic value of ANAs remains unknown. The aim of this study was to evaluate the role of ANAs as a prognostic factor in CLL. METHODS: This study retrospectively analyzed clinical data from 216 newly diagnosed CLL subjects with ANAs test from 2007 to 2017. Multivariate Cox regression analyses were used to screen the independent prognostic factors related to time to first treatment (TTFT), progression free survival (PFS) and overall survival (OS). Receiver operator characteristic curves and area under the curve (AUC) were utilized to assess the predictive accuracy of ANAs together with other independent factors for OS. RESULTS: The incidence of ANAs abnormality at diagnosis was 13.9%. ANAs positivity and TP53 disruption were independent prognostic indicators for OS. The AUC of positive ANAs together with TP53 disruption was 0.766 (95% confidence interval [CI]: 0.697-0.826), which was significantly larger than that of either TP53 disruption (AUC: 0.706, 95% CI: 0.634-0.772, Pâ=â0.034) or positive ANAs (AUC: 0.595, 95% CI: 0.520-0.668, Pâ<â0.001) in OS prediction. Besides, serum positive ANAs as one additional parameter to CLL-international prognostic index (IPI) obtained superior AUCs in predicting CLL OS than CLL-IPI alone. CONCLUSION: This study identified ANAs as an independent prognostic factor for CLL, and further investigations are needed to validate this finding.
Subject(s)
Antibodies, Antinuclear/blood , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , ADP-ribosyl Cyclase 1/blood , Adolescent , Adult , Aged , Aged, 80 and over , Autoimmunity/physiology , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Mutation/genetics , Proportional Hazards Models , Retrospective Studies , Survival Analysis , Tumor Suppressor Protein p53/blood , Young Adult , ZAP-70 Protein-Tyrosine Kinase/bloodABSTRACT
Antigenic stimulation is considered as a possible trigger of neoplastic transformation in chronic lymphocytic leukemia (CLL). B-cell receptor plays a key role in the interactions between the microenvironment and leukemic cells; however, an important role has also been attributed to Toll-like receptors (TLRs). It is believed that disorders of TLR expression may play a part in the pathogenesis of CLL. In this study, we investigated the potential role of TLR2 in CLL by analyzing its expression on leukemic B cells in correlation with clinical and laboratory parameters characterizing disease activity and patients' immune status. We assessed the frequencies of TLR2+/CD19+ cells by the flow cytometry method in peripheral blood of 119 patients with CLL. The percentage of TLR2+/CD19+ cells was significantly lower in patients with CLL as compared to the healthy volunteers. There was also a lower percentage of TLR2+/CD19+ cells in CLL patients with poor prognostic factors, such as ZAP70 and/or CD38 expression, 17p and/or 11q deletion. On the other hand, among patients with del(13q14) associated with favorable prognosis, the percentage of TLR2+/CD19+ cells was higher than among those with del(11q22) and/or del(17p13) as well as in the control group. We found an association between low percentage of CD19+/CD5+/TLR2+ cells and shorter time to treatment. We also demonstrated the relationship between low percentage of CD19+/CD5+ TLR2-positive and overall survival (OS) of CLL patients. CLL patients with a proportion of 1.6% TLR2-positive B CD5+ cells (according to the receiver operating characteristic curve analysis) or more had a longer time to treatment and longer OS than the group with a lower percentage of TLR2 positive cells. To sum up, the results of the study suggest that low TLR2 expression is associated with poor prognosis in CLL patients. The monitoring of CD19+/CD5+/TLR2+ cells number may provide useful information on disease activity. Level of TLR2 expression on leukemic B cells may be an important factor of immunological dysfunction for patients with CLL. Our study suggests that TLR2 could becomes potential biological markers for the clinical outcome in patients with CLL.
Subject(s)
B-Lymphocytes/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Toll-Like Receptor 2/immunology , Aged , Aged, 80 and over , Antigens, CD19/blood , Antigens, CD19/immunology , B-Lymphocytes/metabolism , CD5 Antigens/blood , CD5 Antigens/immunology , Case-Control Studies , Chromosome Aberrations , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Time Factors , Toll-Like Receptor 2/blood , Treatment Outcome , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/immunologyABSTRACT
As novel strategies for treatment and prognostication of chronic lymphocytic leukemia (CLL) evolve, the traditional Rai and Binet systems can now be updated with more modern prognostic markers. This is a review of the latest articles which combine studies from major CLL centers to summarize major prognostic factors for patients diagnosed with CLL. The prognostic information can be categorized into three categories: genetic abnormalities which include 17p, 11q, and immunoglobulin heavy chain variable (IGHV) abnormalities; biochemical abnormalities and cell surface markers which include serum thymidine kinase, ß-2-microglobulin, CD49d, CD38, and ZAP-70 levels; and patient characteristics which include sex, age, and performance status.
Subject(s)
Biomarkers/blood , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosome Aberrations , Humans , Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Prognosis , Thymidine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/blood , beta 2-Microglobulin/bloodABSTRACT
BACKGROUND: In this study, we aimed to determine a cutoff level for CD38 that would aid us in identifying chronic lymphocytic leukemia patients in need of early therapy and predicting patients at sufficiently low risk who would likely exhibit a rapid improvement; we also aimed to find out if CD38 expression would show variability during disease course and determine the extent of CD38 expression. METHODS: 124 patients were diagnosed with CLL. CD38 and ZAP-70 expression levels were measured with four color flowcytometry. Time from diagnosis to initial therapy was calculated for all patients. CD38 expression was studied for a second time during follow-up in 50 patients. RESULTS: For cutoff levels of 7%, 20%, and 30%, CD38 expressions were 61.3%, 25%, and 24.2%, respectively. At all three cutoff levels there were significant correlations with all parameters except age between CD38+ vs. CD38- groups (p < 0.001). The comparative rates of starting therapy for cutoff levels of 7%, 20%, and 30% in CD38+ and CD38- groups were 77.5% vs. 6.25%; 100% vs. 30.7%, and 100% vs. 31.5%, respectively (p < 0.001). Multiple Cox Proportional Hazards Regression analysis: for a cutoff level of 7%, survival was affected by STAGE, ZAP70, and CD38. CONCLUSIONS: A CD38 cutoff level of 7% determined by standardized laboratory techniques is an important prognostic marker. However, the number and frequency of repeat measurements of CD38 expression, and cutoff level of CD38 expression that significantly predict disease prognosis should be further determined by future cohort studies.
Subject(s)
ADP-ribosyl Cyclase 1/blood , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Membrane Glycoproteins/blood , ZAP-70 Protein-Tyrosine Kinase/blood , Adult , Age Factors , Aged , Aged, 80 and over , Cohort Studies , Female , Flow Cytometry , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Male , Middle Aged , Prognosis , Reference Values , Regression Analysis , Retrospective Studies , Survival Analysis , Time-to-TreatmentABSTRACT
BACKGROUND: In recent years, the clinical and biological features governing the clinical course of chronic lymphocytic leukemia (CLL) have been most extensively studied. Human leukocyte antigen-G (HLA-G) allows tumor cells to escape from the antitumor effect of the immune system. Recent studies have shown that various tumor cells show an increased HLA-G expression. Data regarding HLA-G expression in CLL are limited and controversial. The aim of this work is to evaluate flow cytometry study of HLA-G expression on cell surface and assess its relationship with other prognostic factors (CD38, ZAP70, beta 2 microglobulin [ß2MG]) in patients with CLL. DESIGN AND METHODS: Forty-five newly diagnosed CLL cases. White blood cell count, lymphocyte absolute count, hemoglobin level, platelet count, serum lactate dehydrogenase activity, and serum ß2MG level were studied at admission. In each patient, morphologic diagnosis of B-CLL was confirmed by flow cytometry HLA-G, CD38 and ZAP70 expression levels were measured with four-color flow cytometry. RESULTS: HLA-G positivity ranged between 1% and 12% in CLL patients. A significant correlation was found with CD38, ZAP70, disease stage, and ß2MG (P < 0.001). The off-treatment follow-up period was longer in the HLA-G negative group (P < 0.022). CONCLUSIONS: In conclusion, we suggest that, in addition to other prognostic factors, surface HLA-G expression can be considered as an independent prognostic factor. However, our work should be confirmed by further prospective studies, a longer off-treatment follow-up period, and a standardized method.
Subject(s)
HLA-G Antigens/blood , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Aged , Antigens, Tumor-Associated, Carbohydrate/metabolism , Female , Flow Cytometry , Histocompatibility Antigens Class I/blood , Humans , L-Lactate Dehydrogenase/blood , Leukocyte Count , Lymphocyte Count , Male , Middle Aged , ROC Curve , ZAP-70 Protein-Tyrosine Kinase/bloodSubject(s)
Biomarkers, Tumor/blood , Blood Specimen Collection/methods , Leukemia, Lymphocytic, Chronic, B-Cell/blood , ZAP-70 Protein-Tyrosine Kinase/blood , Biomarkers, Tumor/metabolism , Blood Specimen Collection/instrumentation , Clinical Trials as Topic , Humans , Immunoblotting , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Reproducibility of Results , ZAP-70 Protein-Tyrosine Kinase/metabolismABSTRACT
Ewing sarcoma (ES) is a group of highly aggressive small round cell tumors of bone or soft tissue with high metastatic potential and low cure rate. ES tumors are associated with a rapid osteolysis and necrosis. The currently accepted clinical prognostic parameters do not accurately predict survival of high-risk patients. Moreover, neither the subtype of EWS-FLI1/ERG in the tumor, nor the detection of fusion transcripts in the peripheral blood (PB) samples, has prognostic value in ES patients. We evaluated the prevalence of circulating tumor cells (CTCs) in 34 adult ES patients. Since CTCs were confirmed in only small subset of patients, we further explored the expression profiles of PB leukocytes using a panel of genes associated with immune system status and increased tumor invasiveness. Moreover, we analyzed the alterations of the routine blood tests in the examined cohort of patients and correlated our findings with the clinical outcome. A uniform decrease in ZAP70 expression in PB cells among all ES patients, as compared to healthy individuals, was observed. Monocytosis and the abnormal expression of CDH2 and CDT2 genes in the PB cells significantly correlated with poor prognosis in ES patients. Our study supports the previously proposed hypothesis of systemic nature of ES. Based on the PB cell expression profiles, we propose a mechanism by which immune system may be involved in intensification of osteoclastogenesis and disease progression in ES patients. Moreover, we demonstrate the prognostic value of molecular PB testing at the time of routine histopathological diagnosis.
Subject(s)
Blood Cells/physiology , Bone Neoplasms/genetics , Gene Expression Profiling , Sarcoma, Ewing/genetics , Adult , Antigens, CD/genetics , Blood Cells/pathology , Bone Neoplasms/blood , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Cadherins/genetics , Case-Control Studies , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Nuclear Proteins/genetics , Oncogene Proteins, Fusion/genetics , Prognosis , Proto-Oncogene Protein c-fli-1/genetics , RNA-Binding Protein EWS/genetics , Sarcoma, Ewing/blood , Sarcoma, Ewing/mortality , Sarcoma, Ewing/pathology , Transcription Factors/genetics , Ubiquitin-Protein Ligases/genetics , Young Adult , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/geneticsABSTRACT
Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, but its pathogenesis is still poorly understood. Interleukin-9 (IL-9) is initially described as a growth factor secreted by helper T cells. Recently, the oncogenic activities of IL-9 were reported in some leukemia but not chronic lymphocytic leukemia (CLL). The purpose of the present study is to investigate the expression of IL-9 from patients with CLL and to evaluate its correlation with clinical characteristics. Serum and peripheral blood mononuclear cells (PBMCs) from patients with CLL were analyzed using ELISA, RT-PCR, and western blot. ELISA analysis indicated IL-9 could be detected in 20 of 47 sera from CLL patients while none serum sample from healthy volunteers contained detectable levels of IL-9. There was a higher expression of IL-9 within PBMCs from patients with CLL compared with B cells of healthy blood donors using RT-PCR and western blot. The upregulated IL-9 was correlated to the clinical staging, ZAP-70 expression, ß2 microglobulin expression and IgVH status of CLL patients (P<0.05). Our findings suggest that overexpression of IL-9 may contribute to the pathogenesis of CLL and is associated with some adverse prognostic parameters.
Subject(s)
Biomarkers, Tumor/blood , Interleukin-9/blood , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukocytes, Mononuclear/immunology , Biomarkers, Tumor/genetics , Blotting, Western , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin Heavy Chains , Immunoglobulin Variable Region , Interleukin-9/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Male , Middle Aged , Neoplasm Staging , RNA, Messenger/blood , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation , ZAP-70 Protein-Tyrosine Kinase/bloodABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. It is characterized by heterogeneous clinical course of the disease and new prognostic factors are still needed. CD74 plays an important role in signal transduction in B cell proliferation and survival pathway. CD74 expression has been shown in solid tumors and has been connected with poor prognosis and tumor progression. The aim of the study was to evaluate the expression of CD74 in chronic lymphocytic leukemia patients with combination with other known prognostic factors. Expression of CD74 was determined in 90 patients and 28 healthy controls. CD74 expression was significantly higher in CLL group than in controls. There was positive correlation between CD74 and ZAP70 expression (p = 0.008). High expression of CD74 was positively correlated with more advanced stage of the disease (p = 0.02). No correlation was shown between CD74 and sex, mutational status IgVH and time to first treatment.
Subject(s)
Antigens, Differentiation, B-Lymphocyte/biosynthesis , Histocompatibility Antigens Class II/biosynthesis , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , ZAP-70 Protein-Tyrosine Kinase/biosynthesis , Adult , Aged , Aged, 80 and over , Analysis of Variance , Antigens, Differentiation, B-Lymphocyte/blood , Antigens, Differentiation, B-Lymphocyte/metabolism , C-Reactive Protein/metabolism , Case-Control Studies , Female , Histocompatibility Antigens Class II/blood , Histocompatibility Antigens Class II/metabolism , Humans , Kaplan-Meier Estimate , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Male , Middle Aged , Receptors, IgE/blood , Receptors, IgE/metabolism , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/metabolismSubject(s)
ADP-ribosyl Cyclase 1/blood , Interleukins/blood , Leukemia, Lymphocytic, Chronic, B-Cell/blood , ADP-ribosyl Cyclase 1/genetics , Aged , Aged, 80 and over , Case-Control Studies , Female , Gene Expression , Humans , Immunoglobulin Heavy Chains/blood , Immunoglobulin Heavy Chains/genetics , Interleukins/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Middle Aged , Signal Transduction , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/genetics , Interleukin-22ABSTRACT
Protein tyrosine kinases (PTKs) play an important role in T cell development and activation. In vitro and in vivo defects, resulting in variable deficiencies in thymic development and in T cell antigen receptor (TCR) signal transduction, in PTKs have been shown. ZAP70, one of those PTKs, is a 70-kDa tyrosine phosphoprotein and associates with the ζ chain and undergoes tyrosine phosphorylation following TCR stimulation. It is expressed in T and natural killer (NK) cells. Several mutations were shown to lead to an autosomal recessive form of severe combined immunodeficiency disease (SCID). Here, we present a family with a novel mutation in ZAP70. The proband, the second child of the first cousin parents of Turkish origin, was diagnosed with SCID having R514C mutation on homozygous state. She had decreased CD8(+) T and natural killer cells, normal CD4(+) T cells, high serum Ig E level, perivascular dermatitis and ichthyosis. This article presents clinical features of a novel mutation on ZAP70 and the first prenatal molecular diagnosis of ZAP70 deficiency. Different mutations in ZAP70 and related phenotypes reported in the literature are also discussed.
Subject(s)
Mutation, Missense , Prenatal Diagnosis , Severe Combined Immunodeficiency , ZAP-70 Protein-Tyrosine Kinase/genetics , Adult , Amino Acid Substitution , CD8-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/pathology , Child, Preschool , Dermatitis/blood , Dermatitis/diagnosis , Dermatitis/genetics , Dermatitis/pathology , Family , Female , Humans , Ichthyosis/blood , Ichthyosis/diagnosis , Ichthyosis/genetics , Ichthyosis/pathology , Immunoglobulin E/blood , Killer Cells, Natural/metabolism , Killer Cells, Natural/pathology , Lymphocyte Count , Male , Pedigree , Pregnancy , Severe Combined Immunodeficiency/blood , Severe Combined Immunodeficiency/diagnosis , Severe Combined Immunodeficiency/genetics , Severe Combined Immunodeficiency/pathology , T-Lymphocytes, Regulatory/metabolism , T-Lymphocytes, Regulatory/pathology , Turkey , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/deficiencyABSTRACT
BACKGROUND: Copper levels are elevated in cancer patients compared to normal subjects. However, few studies have investigated the relationship between copper and hematological malignancies. METHODS: 84 patients with hematological diseases were studied, along with 50 healthy individuals. Copper was measured by flame atomic absorption spectrometry. The patients were classified to 2 homogeneous groups, acute and chronic hematological neoplasms, respectively. For the patients with acute hematological malignancies, relapse and remission were investigated in relation to serum copper levels. For chronic hematological neoplasms, serum copper was connected either with stable or progressive disease. Zeta-chain-associated protein kinase 70 (ZAP70) and CD38 expression, along with the unmutated VH immunoglobulin genes (IgVH) status were also determined for the 22 chronic lymphocytic leukemia (CLL) patients. RESULTS: 54 patients with relapse or progressive disease had elevated copper levels (mean value 1.8 mg/l), whereas 30 patients either in remission or in stable disease had normal copper levels (mean value 1.01 mg/l) (normal range 0.8-1.3mg/l). CONCLUSION: Hence, our study indicates that serum elevated copper levels are associated with hematological malignancies either in relapse or in disease progression, whereas normal copper levels are linked with hematological neoplasms in remission or in stable disease. Furthermore, we report for the first time an association between high serum copper levels and several adverse prognostic markers in CLL, such as increased expression of ZAP70 and CD38, along with elevated percentage of unmutated IgVH.
Subject(s)
Copper/blood , Hematologic Neoplasms/blood , ADP-ribosyl Cyclase 1/blood , Acute Disease , Adolescent , Adult , Aged , Biomarkers, Tumor/blood , Chronic Disease , Disease Progression , Female , Humans , Immunoglobulin Variable Region/blood , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Myeloid, Acute/blood , Lymphoma/blood , Male , Membrane Glycoproteins/blood , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Recurrence , Remission Induction , Young Adult , ZAP-70 Protein-Tyrosine Kinase/bloodABSTRACT
The aim of our study was to analyze the serum levels of advanced oxidation protein products (AOPPs) and advanced glycation end products (AGEs), and protein nitrosylation in patients with B-chronic lymphocytic leukemia (B-CLL). AOPPs, AGEs, and S-nitrosylated were increased in B-CLL patients. The mutation of IgVH gene, CD 38, and Zap 70 expression were not associated with increased oxidative stress. The mutant 2677GT genotype was found to be associated with higher AGEs levels with respect to wild-type genotype, while as far the C3435T MDR1 polymorphism is concerned, subjects presenting wild-type genotype showed higher values of AOPPs with respect to heterozygous genotype. Our results suggest that B-CLL is associated with oxidative stress.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Glycation End Products, Advanced/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Oxidative Stress , Proteins/metabolism , ADP-ribosyl Cyclase 1/biosynthesis , ADP-ribosyl Cyclase 1/blood , ADP-ribosyl Cyclase 1/genetics , ATP Binding Cassette Transporter, Subfamily B , Aged , Aged, 80 and over , Blood Proteins/analysis , Blood Proteins/metabolism , Female , Humans , Immunoglobulin Heavy Chains/blood , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Lymphokines/blood , Lymphokines/genetics , Male , Middle Aged , Nitrosation , Oxidation-Reduction , Polymorphism, Single Nucleotide , Proteins/analysis , Sialoglycoproteins/blood , Sialoglycoproteins/genetics , ZAP-70 Protein-Tyrosine Kinase/blood , ZAP-70 Protein-Tyrosine Kinase/geneticsABSTRACT
INTRODUCTION: Zeta-chain-associated protein kinase 70 (ZAP-70) has been identified as an independent prognostic marker in chronic lymphocytic leukemia (CLL). Based on our previous studies, we have developed a combined one-tube technology with multiple internal controls to optimize ZAP-70 assessment. METHODS: Forty-eight untreated CLL cases were examined for ZAP-70 expression using a modified 7-color one-tube assay. Normal donor (ND) whole blood is stained with CD3 APC-Cy7 and CD19 APC. In a second tube, patient whole blood is stained with CD5 PE-Cy7, CD19 PerCP-Cy5.5, and CD20 eFluor450. After surface staining and fixation, these two tubes are combined. After saponin permeabilization, the cells were stained with two anti-ZAP-70 clones (1E7.2/AF488 and SBZAP/PE). The results obtained from this modified tube were compared with those obtained concurrently using the non-mixed single sample tubes. Five different methods of ZAP-70 expression analysis were evaluated: percentage positive cells using ND T-cells as a reference; the internal patient T-cell/clone ratio; ND T-cell/clone ratio; clone/ND B-cell ratio; and modified Z-index. RESULT: Overall, the combined patient and ND mix tube performed better than the non-mixed single sample tube. The strongest correlations between ZAP-70 expression and immunoglobulin heavy chain variable (IGHV) mutational status were seen with percentage positive ND T-cell, ND T-cell/clone ratio, and clone/ND B-cell ratio for both 1E7.2 and SBZAP clone (P < 0.0001). CONCLUSION: The modified one tube method combining the ND and patient sample provides highly reliable results that correlate with the IGHV mutational status. This method should be considered as part of the next step in standardization of the ZAP-70 assay in CLL.
Subject(s)
Flow Cytometry/methods , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , ZAP-70 Protein-Tyrosine Kinase/analysis , ZAP-70 Protein-Tyrosine Kinase/blood , Aged , Aged, 80 and over , Antibodies, Monoclonal , Antigens, CD19/immunology , Antigens, CD20/immunology , B-Lymphocytes/cytology , Biomarkers, Tumor/analysis , Biomarkers, Tumor/biosynthesis , CD3 Complex/immunology , CD5 Antigens/immunology , Female , Humans , Immunoglobulin Heavy Chains/analysis , Immunoglobulin Heavy Chains/genetics , Male , Middle Aged , Staining and Labeling/methods , T-Lymphocytes/cytologyABSTRACT
BACKGROUND: Flow cytometric immunophenotyping has an established role in the diagnosis and monitoring of B-lymphoblastic leukemia (B-LL). However, the search continues for an optimal reagent set that can identify leukemic blasts with specificity, reproducibility, and sensitivity, at any point during the course of the disease and in every specimen type. METHODS: This study evaluated the diagnostic utility of detecting the intracytoplasmic antigens zeta-associated protein (ZAP-70) and Bcl-2 in the distinction between the leukemic blasts of B-LL and hematogones. RESULTS: In comparison with hematogones in reference specimens, significantly higher levels of Bcl-2 were identified in 21 of 23 (91%) B-LL. In particular, Bcl-2 expression was consistently higher in leukemic blasts with bright intensity CD10 expression than the equivalent most immature (CD10 bright intensity) hematogones. As previously reported, Bcl-2 expression was lower in B-LL with BCR-ABL1 gene rearrangement, but the fluorescence intensity of this group of specimens was still significantly higher than that seen for hematogones. In contrast, ZAP-70 was expressed at significantly higher levels in only 7 of 23 (30%) B-LL and demonstrated other findings that might limit clinical utility, including differences in the level of ZAP-70 expression during therapy and between blasts in the peripheral blood and bone marrow. CONCLUSIONS: Bcl-2 over-expression provides a useful tool for the distinction between B-LL and hematogones. In contrast, although further optimization of the ZAP-70 assay might increase the sensitivity of detection, over-expression of ZAP-70 was identified in only a minority of B-LL.
Subject(s)
Flow Cytometry/methods , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , ZAP-70 Protein-Tyrosine Kinase/biosynthesis , ZAP-70 Protein-Tyrosine Kinase/blood , Adolescent , Adult , Aged , B-Lymphocytes/pathology , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Child , Child, Preschool , Female , Humans , Immunophenotyping/methods , Infant , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Young AdultABSTRACT
INTRODUCTION: Expression of ZAP-70 by chronic lymphocytic leukemia (CLL) is associated with more aggressive disease and can help differentiate CLL using mutated immunoglobulin heavy chain variable genes (VH) from cases expressing unmutated VH genes. However, flow cytometric detection of ZAP-70 in CLL shows considerable variability and may be of questionable significance because most laboratories cannot correlate their results to clinical outcome or VH mutational data. METHODS: Seventy cases of CLL were evaluated for ZAP-70 using a previously optimized staining procedure and two different methods to eliminate nonspecific background staining. One method, not previously reported, used isotypic control antibodies, where the concentrations were adjusted/optimized so that normal B-cells stained negatively for ZAP-70. The other used ZAP-70 stained peripheral blood B-cells from normal donors. The percentages of ZAP-70 stained CLL cells above the two thresholds were compared. RESULTS: Concentrations of isotypic control antibodies had to be increased from manufacture's recommendations to insure normal B-cells were ZAP-70 negative. ZAP-70 levels among the CLL cases formed a bimodal distribution using the optimized isotypic control threshold, with 30 having low values (0-32% positive) and 40 high values (60-99% positive). In contrast, a continuous distribution was obtained with the ZAP-70 stained B-cell threshold. VH mutational status strongly correlated with the optimized control values as 29/30 low ZAP-70 cases had mutated VH genes and 37/40 high ZAP-70 cases used unmutated VH genes. CONCLUSIONS: Use of an optimized isotypic control threshold could increase the reliability of flow based ZAP-70 detection and correlates well with VH mutational status.
Subject(s)
Flow Cytometry/methods , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , ZAP-70 Protein-Tyrosine Kinase/analysis , ZAP-70 Protein-Tyrosine Kinase/blood , Antibodies, Monoclonal , B-Lymphocytes/cytology , B-Lymphocytes/immunology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/immunology , Humans , Immunoglobulin Heavy Chains/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Reproducibility of Results , ZAP-70 Protein-Tyrosine Kinase/immunologyABSTRACT
OBJECTIVES: To evaluate carbonyl groups (CG) serum levels in B-chronic lymphocytic leukemia (B-CLL) patients. DESIGN AND METHODS: CG serum levels were assessed in 48 B-CLL patients and in 30 control subjects. RESULTS: CG were increased in B-CLL patients. We found a positive correlation between CG with CD38 expression and a negative correlation with ZAP 70 expression. CONCLUSIONS: B-CLL patients displayed an unbalance of the oxidative stress. CG serum levels could be considered as a prognostic factor in B-CLL.
Subject(s)
Biomarkers, Tumor/blood , Blood Proteins/metabolism , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Protein Carbonylation , ZAP-70 Protein-Tyrosine Kinase/blood , ADP-ribosyl Cyclase 1 , Aged , Aged, 80 and over , Catalase/blood , Female , Humans , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/physiopathology , Male , Malondialdehyde/blood , Membrane Glycoproteins , Middle Aged , Neoplasm Staging , Oxidative Stress , PrognosisABSTRACT
In the light of recent data showing survival improvement of patients with chronic lymphocytic leukemia (CLL), we investigated clinical characteristics and survival patterns of patients with CLL over the last 40 years in Israel. Demographic and clinical data collected in the database of the Israeli CLL Study Group were analyzed. Of the 1,325 patients, 221 were diagnosed during the time period 1968-1989, 456 during 1990-1999, and 639 during 2000-2010. There was shift toward older age (median, 71 vs. 68 vs. 66 years) and a higher proportion of patients at Binet stage A at diagnosis (77.6% vs. 66.7% vs. 60.3%) in the more recent time periods. Median survival for the entire cohort was 10.9 years; 12.2 years for patients diagnosed at Binet stage A, 8.5 years for stage B, and 6.4 years for stage C patients. Older age, high-beta 2-microglobulin level, and expression of ZAP-70 predicted shorter survival. There were no apparent changes over time regarding gender, age or different clinical stages. Young patients with Binet stage A had lower life expectancy than the general population; but, in older ages, the survival rates were comparable. There were increased proportions of CLL patients diagnosed in early stages, and, at older age, during the last decades, however, survival rates according to sex, age, or stage remained stable. CLL continues to be an incurable disease affecting survival even in patients diagnosed at early stages. Survival benefit shown in recent trials using chemoimmunotherapy has still to be proven in wider general practice.